Key Highlights: Primary endpoint met: ~1.72.0% A1C reduction at 40 weeks vs ~0.8% placebo Significant weight loss: ~1517% reduction vs ~2.5% placebo Sustained efficacy: No weight-loss plateau observed over study duration Triple mechanism: Targets GLP-1, GIP & glucagon receptors for amplified metabolic effects Convenient dosing: Once-weekly injectable therapy Why It Matters: Beyond GLP-1: Signals the shift to multi-hormone incretin therapies Dual efficacy: Combines deep A1C reduction + substantial weight loss Competitive edge: Strengthens Lillys position vs semaglutide & tirzepatide Holistic impact: Potential to improve broader cardiometabolic outcomes Key Takeaway: Retatrutide is emerging as a potential best-in-class metabolic therapy, combining powerful glucose lowering with significant weight loss
Hepatology 60 , 715735 (2014)
Rasmussen LB, Ovesen L, Bulow I, Knudsen N, Laurberg P, and Perrild H (2000)
Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein
However, experts have debunked the theory that tanning booths offer the same benefits as medicinal light therapy, which involves exposure to either ultraviolet light B (UVB) or ultraviolet light A (UVA) the latter of which requires the administration of the light-sensitizing agent psoralens, applied in a cream or taken orally
Ye J, Huang Q, Xu J, Huang J, Wang J, Zhong W, Chen W, Lin X, Lin X
